Navigation Links
Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
Date:12/8/2012

r 65 years old, after a median follow up of 20.3 months
  • 71 percent in patients with RR disease, including patients with HR CLL/SLL, after a median follow up of 15.7 months
    • The estimated PFS at 26 months is 96 percent for patients over 65 years of age with TN CLL and 75 percent for those with RR/HR disease
      • Estimated OS at 26 months is 96 percent in TN patients and 83 percent in patients with RR/HR disease

    Responses were independent of high-risk clinical or genetic features, such as a deletion of part of chromosome 17 (del17p).

    Most adverse events (AEs) were Grade 1 or 2 in severity, with the most common attributed to ibrutinib being diarrhea, fatigue, nausea and rash. Adverse hematologic events were relatively infrequent. In patients with cytopenia (low blood cell counts) at the beginning of the study, sustained improvements of platelet counts (78 percent) and hemoglobin (82 percent) were seen after treatment. There was no evidence of cumulative toxicity or long-term safety concerns.

    Oral presentation 187, The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients
    Jan A. Burger, M.D., Ph.D., MD Anderson Cancer Center, Houston, TX

    This presentation was based on findings from a Phase 2, single-center trial with 40 patients with HR CLL treated with 420 mg/day ibrutinib in combination with rituximab, a current standard CLL therapy. Patients with HR disease were previously treated and had one of the following characteristics: deletion of a part of chromosome 17 (del17p), which is associated with poorer treatment outcomes; a gene mutation called TP53; del11q, another partial chromosome deletion associated with poorer outcomes; or a short remission duration (less than three years) after first-line chemo-
    '/>"/>

    SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
    2. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
    3. Startling results in synthetic chemistry presented in Nature Chemistry
    4. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
    5. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
    6. Top Contenders For the First Annual 2012 Fright Night Awards Presented By Cancer Bites Announced
    7. Promising Data Presented on GenVec Malaria Program
    8. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
    9. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
    10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    11. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
    (Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
    (Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
    (Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., ... the relaunch of his highly informative blog, now named Stem ... What are Stem Cells ?” Dr. Harman’s purpose for ... the basics of stem cell therapy so that pet owners ... treatment when considering regenerative medicine. , A veterinarian by trade, ...
    Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
    ... Dec. 10, 2010 bioTheranostics, a bioMerieux company that ... management, announced today new findings from a clinical study ... molecular oncology test. Data from the study were presented ... Symposium (SABCS). The company also announced ...
    ... Agrivida, Inc. today announced a collaboration with ... will provide low-cost sugars for a variety of ... Syngenta licenses to Agrivida access to crop technology ...   Agrivida will bolster its existing ...
    ... athletes reach the top of their game when preparing ... performance sports agency, has reached an agreement to become ... by Argento Diagnostics to improve training programmes for athletes. ... proteins which reveal details about the condition of the ...
    Cached Biology Technology:bioTheranostics' Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients 2bioTheranostics' Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients 3Agrivida Announces Collaboration With Syngenta Ventures to Deliver Low-Cost Sugars for Cellulosic Biofuels and Biochemicals 2Medical science helps UK athletes reach peak performance 2Medical science helps UK athletes reach peak performance 3
    (Date:7/10/2014)... 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused ... Gino Pereira was interviewed on July 1 st ... Florida . Mr. Pereira discusses the company,s next generation ... and how the Wocket™ aims to replace a traditional wallet ... Cedric Harris tells Gino he has never heard of ...
    (Date:7/10/2014)... DUBLIN , July 3, 2014 ... the addition of the "Global Gesture Recognition ... Market - Forecasts to 2020" report to ... Global Gesture Recognition & Touch-Less Sensing ... been around for a while, but the companies ...
    (Date:7/10/2014)... 7, 2014 According to a ... Access Control Systems Market Global Forecast, Market Share, Size, ... Electronic Access Control systems market was valued at USD ... at a CAGR of 12.6% from 2014 to 2019, ... in 2019. Browse the full Electronic Access ...
    Breaking Biology News(10 mins):Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5
    ... New evidence reported in the August issue of Cell Stem ... on how the HIV/AIDS virus leads to learning and memory ... on the surface of the virus not only kills some ... also prevents the birth of new brain cells by crippling ...
    ... two proteins that bind to messenger RNA, a molecule ... into proteins, triggers the appearance of fragile X-associated tremor/ataxia ... that causes fragile X syndrome in children, said researchers ... University School of Medicine in a report that appears ...
    ... Aug. 15, 2007 A mysterious epidemic of thyroid ... be linked to exposure to dust shed from flame ... scientists are reporting in a study scheduled for publication ... Technology, a semi-monthly journal from the American Chemical Society, ...
    Cached Biology News:HIV is a 'double hit' to the brain 2Researchers identify proteins involved in new neurodegenerative syndrome 2Study links cat disease to flame retardants in furniture and to pet food 2Study links cat disease to flame retardants in furniture and to pet food 3